Biologic medications provide opportunities to improve the health, safety, quality of life, and long-term outcomes of patients with moderate-to-severe uncontrolled asthma. This article provides primary care nurse practitioners with an overview of the pathophysiology of Type 2 inflammation in asthma, the mechanism of action of biologics approved for asthma, monitoring considerations, and practice considerations.
No takes yet. Share an insight, caveat, or question.
Mara Thrasher (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: